Early Aldosterone Blockade in Acute Heart Failure: An Exploratory Safety

Status Withdrawn

Clinical Trial Summary

Over one million hospitalizations for acute heart failure (AHF) occur over every year in the United States, resulting in high mortality, re-hospitalizations, and incurred financial costs; yet nearly every attempt over the last 10 years to improve outcomes with novel therapies have all failed. In this proposal, we will study whether a generic drug known as a mineralocorticoid receptor antagonist (more commonly known as an aldosterone blocker), proven to reduce morbidity and mortality for chronic heart failure patients, is safe and feasible to give to AHF patients in the emergency department and during hospitalization for a total of 3 days. The results of this study will provide necessary and sufficient data to design an efficacy study in a larger population to test whether early use of a high-dose of mineralocorticoid receptor antagonists will reduce post-discharge morbidity and mortality.

Clinical Trial Description

This clinical trial pilot study - Early Aldosterone Blockade in Acute Heart Failure: An Exploratory Safety Study - will explore the safety of early mineralocorticoid receptor blockade with high-dose spironolactone (100mg/daily), an oral mineralocorticoid receptor antagonist, versus placebo (both in addition to standard therapy), in patients admitted with acute heart failure (AHF) for 3 days. Aim 1 will answer the critical question that early mineralocorticoid receptor (MR) antagonism in AHF patients is sufficiently safe to move forward with a definitive trial. Aim 2 will demonstrate feasibility of patient enrollment and compliance with treatment throughout the study to inform future study design and enrollment projections. This study will provide the necessary and sufficient data in order to plan a larger, simple, definitive trial to test the hypothesis that early aldosterone blockade in AHF patients will reduce mortality and 30-day readmissions.

The primary endpoint for the pilot study will be the difference in incidence of mean change of serum potassium of a specific amount from baseline to 120 hours from initial dose between placebo vs. spironolactone treated subjects. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02299726
Study type	Interventional
Source	Indiana University
Contact
Status	Withdrawn
Phase	Phase 2
Start date	May 2015
Completion date	November 2018

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT02151383` - Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure	Phase 2
Completed	`NCT02135835` - A Study to Evaluate the Efficacy and Safety of Shenfu Zhusheye in Patients With Acute Heart Failure	Phase 4
Recruiting	`NCT05556044` - Empagliflozin for New On-set Heart Failure Study Regardless of Ejection Fraction	Phase 3
Recruiting	`NCT04363697` - Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)	Phase 4
Completed	`NCT02122640` - Evaluation of Acute Cardiogenic Dyspnoea With Thorax Echography and Pro-BNP in the Emergency Department	N/A
Not yet recruiting	`NCT01211886` - Utility of Brain Natriuretic Peptide (BNP) in Patients With Type IV Cardio-renal Syndrome Admitted to the Intensive Care Unit (ICU)	N/A
Completed	`NCT01193998` - Impact of Validated Diagnostic Prediction Model of Acute Heart Failure in the Emergency Department	N/A
Not yet recruiting	`NCT06465498` - Investigating aCute heArt failuRe Decongestion Guided by Lung UltraSonography	N/A
Recruiting	`NCT05276219` - Optimized Treatment of Pulmonary Edema or Congestion	Phase 4
Recruiting	`NCT05392764` - Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure	Phase 3
Recruiting	`NCT03157219` - Manipal Heart Failure Registry (MHFR)	N/A
Completed	`NCT06024889` - Acute Effects of Furosemide on Hemodynamics and Pulmonary Congestion in Acute Decompensated Heart Failure.	Phase 1/Phase 2
Terminated	`NCT04174794` - Investigating Reduction of aCute heArt Failure Readmission With Lung UltraSound-preliminary Trial
Recruiting	`NCT05972746` - Telemonitoring Program in the Vulnerable Phase After Hospitalization for Heart Failure	N/A
Enrolling by invitation	`NCT02258984` - Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial	N/A
Completed	`NCT02141607` - Evolution of Molecular Biomarkers in Acute Heart Failure Induced by Shock
Completed	`NCT01870778` - Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF	Phase 3
Recruiting	`NCT05986773` - Diuretic Strategies in Acute Heart Failure Patients at High Risk for Diuretic Resistance	Phase 4
Recruiting	`NCT04163588` - Sequential Nephron Blockade in Acute Heart Failure	Phase 3
Recruiting	`NCT04329234` - Korean Heart Failure Registry III

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.